Patients' Pain Anxiety Levels Vary Depending on the Type of Pain, the Patient's Gender, and Pain Duration

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

Although patients with cancer pain reported lower levels of current pain than did patients with benign or treatmentrelated pain, their pain anxiety levels were higher, Mikki Miner, RN, MS, said in a poster presentation at the 8th World Congress on Pain.

BUFFALO, NY-Although patients with cancer pain reported lowerlevels of current pain than did patients with benign or treatmentrelatedpain, their pain anxiety levels were higher, Mikki Miner, RN,MS, said in a poster presentation at the 8th World Congress onPain.

Ms. Miner and her colleagues at the Roswell Park Cancer Institutesurveyed 283 outpatients on the Pain Management Service--150 withcancer pain, 40 with treatment-related pain, and 93 with chronicbenign pain--using several psychometric scales for pain anxiety.

The cancer pain patients reported lowest present pain and leastpain within 24 hours, but had higher scores on the pain anxietyscales than the other two groups.

Interestingly, of the four domains of the Pain Anxiety SymptomsScale (PASS)--fear, cognitive anxiety, escape avoidance, and somaticanxiety--females had higher levels of fear and cognitive anxietythan did men.

The study also showed a temporal pattern to pain anxiety acrossall three groups: pain anxiety was highest among patients withpain for more than 6 months but less than 1 year.

"Some of these findings are very intuitive," Ms. Minersaid. "After 6 months of pain, you become anxious. Certainly,the cancer patients would have more anxiety, and that did holdup in this study. It also makes perfect sense for the other twogroups: If you were still in pain 6 months after your trauma ortreatment, you would become anxious."

At the end of 1 year if the pain is still present, Ms. Miner speculatedthat pain anxiety levels drop because patients have either developedother coping skills or the anxiety has changed, maybe into depression.This finding could be helpful in the clinical setting, she noted,since pain and depression are treated differently.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content